NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Allogene Therapeutics, Inc. (ALLO) Stock Analysis

Allogene Therapeutics, Inc. (ALLO) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

ALLO

$1.97

−$0.01 (−0.51%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ALLO with… →

ALLO Key Statistics

As of Sep 4, 2026
Trading
Open
$1.97
Previous Close
$1.98
Day's Range
1.95–2.01
52-Week Range
1.04–4.46
Volume
4.43M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.48
Valuation
Market Cap
$680.62M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
146.68
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.66
Financials (FY)
Revenue (FY)
$0.00−100.00%
Net Income (FY)
−$190.89M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
345.49M
1-Year Return
+77.48%
Dividend and dates
Earnings Date
November 5, 2026
Avg Volume
7.44M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

ALLO Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+43.80%
2025−35.68%
2024−33.64%
2023−48.97%
2022−57.84%
2021−40.89%
2020−2.85%
2019−3.53%
2018 (partial year)+7.72%

As of September 4, 2026.

ALLO Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$190.89M—
2024$22.00K−$257.59M−1170863.6%
2023$95.00K−$327.27M−344489.5%
2022$156.00K−$340.41M−218214.1%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$206.93M−$190.89M—
2024$22.00K—−$257.48M−$257.59M−1170863.6%
2023$95.00K—−$314.49M−$327.27M−344489.5%
2022$156.00K—−$335.54M−$340.41M−218214.1%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ALLO Valuation vs Biotechnology Median

Median of 656 stocks
MetricALLOBiotechnology medianvs median
P/S ratio146.6815.269.6x the median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 9 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Allogene Therapeutics, Inc. (ALLO) is capitalised at $680.62M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 150.

The 52-week range on file runs from $1.04 to $4.46. The most recent close on file for ALLO is $1.97, dated September 4, 2026. That is −$0.01 (−0.51%) against the previous close. The latest close sits 89.42% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. That is −100.00% against the prior fiscal year, when revenue was $22.00K. The same year closed with a net loss of $190.89M. The reported profit margin is 0%. Trailing earnings per share are −0.66.

Across the 4 fiscal years on file, revenue moves from $156.00K in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 146.68. On price-to-sales that is 9.6 times the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

The trailing one-year price return is +77.48%. Across 5 years the annualized return works out at −40.06%. Beta against the wider market is reported at 0.48. Annualized volatility over the trailing 7 years is 79.97%.

Growth & Income

The record shows no dividend for ALLO.

2026 is still running; the price is +43.80% year to date. The strongest complete calendar year on file is 2020 at −2.85%; the weakest is 2022 at −57.84%. Of the 7 complete calendar years on file, 0 finished higher.

Peer Comparison

Allogene Therapeutics, Inc. (ALLO) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Allogene Therapeutics, Inc. ALLO $680.62M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Allogene Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Allogene Therapeutics, Inc.

Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. The company is also developing cemacabtagene ansegedleucel (cema-cel), an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma (LBCL). In addition, it develops ALLO-316, an engineered allogeneic CAR T cell product candidate that targets CD70 to treat renal cell carcinoma (RCC); and ALLO-329, an engineered allogeneic CAR T cell product candidate that targets both CD19 and CD70 for the treatment of autoimmune diseases (AID), such as systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), and systemic sclerosis (SSc). The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Visit website →